Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine–Venetoclax Combination in Developing Countries: A Single-Center Experience
Our single-center experience confirms that AZA-VEN is an effective and feasible therapeutic option for elderly AML patients, with a median survival of 25 months. Hematologic and infectious toxicities remain major challenges. In a North African context, limited access to VEN due to its cost can be partially mitigated through dose adjustments with azole antifungals. Further prospective multicenter studies are warranted.
Authors
- Aznag Mohamed Amine (ORCID: https://orcid.org/0000-0002-4713-2233)
- Rim Chakara
Institutions
- Centre Hospitalier Universitaire Mohammed VI (MA)
- Hôpital Militaire Avicenne (MA)
Publication Details
- Journal
- Cureus
- Published
- 2026-01-26
- DOI
- https://doi.org/10.7759/cureus.102308
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00